Tocopherol Acetate

Summary

Tocopherol Acetate (CHEMBL3989859) is an approved small molecule; indicated across 1 condition including brachial plexus neuropathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 472.7 Da · C31H52O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989859
Name	Tocopherol Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	11305985
Molecular formula	C31H52O3
Molecular weight	472.7
InChIKey	ZAKOWWREFLAJOT-ADUHFSDSSA-N

SMILES: CC1=C(C(=C(C2=C1OC(CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OC(=O)C)C

IUPAC name: [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate

Also known as: .alpha.-tocopherol acetate, Aec tocopheryl acetate, Alpha tocopheryl acetate, Alpha-tocopherol acetate, Copherol 1250 c, Covitol 1100 c, E-tabs, E-vicotrat, Ephynal, Jeen vitamin e, Ronacare tocopheryl acetate, Tinoderm e

Patent coverage: 1,893 distinct patent families (3,637 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
brachial plexus neuropathy	3	MONDO:0006683	EFO:1000844

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01291433	PHASE3	COMPLETED	Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy
NCT02898376	PHASE3	UNKNOWN	Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).